Valproic Acid PCD Pharma Franchise Company
Cafoli Lifecare is a WHO-GMP certified PCD pharma franchise company offering a Valproic Acid range of 4 formulations in tablet form to distributors and franchise partners across India, with district-level monopoly rights. Valproic Acid is a prescription-only, specialist-initiated medicine and is supplied and promoted strictly on that basis.
What is Valproic Acid?
Valproic acid (valproate) is a broad-spectrum antiepileptic drug and mood stabiliser. It raises brain levels of the inhibitory neurotransmitter GABA and blocks voltage-gated sodium channels and T-type calcium channels, which together reduce the abnormal, excessive neuronal firing that produces a seizure. Its breadth is unusual — it is effective across generalised, focal, absence and myoclonic seizure types, which few antiepileptics manage. It is also used in bipolar mania and in migraine prophylaxis. It is prescription-only, requires liver function monitoring, and is contraindicated in pregnancy because of a well-documented risk of serious birth defects and developmental disorders. Compound and pharmacology data are available on PubChem.
Valproic Acid Formulations Available with Cafoli Lifecare
The Valproic Acid portfolio comprises 4 formulations in tablet form, including extended-release presentations used for once-daily dosing. Strength, packing and net rate details are shared on enquiry.
Therapeutic Applications of Valproic Acid
- Generalised tonic-clonic, absence and myoclonic seizures
- Focal seizures, alone or as add-on therapy
- Idiopathic generalised epilepsy syndromes
- Acute mania and maintenance therapy in bipolar disorder
- Migraine prophylaxis, at the specialist's discretion
Prescribers are neurologists, paediatric neurologists, epilepsy specialists and psychiatrists. Prescribing in women and girls of childbearing potential is subject to strict pregnancy-prevention conditions because of the drug's teratogenic risk.
Why Valproic Acid is a High-Potential Molecule for Distributors
Epilepsy is one of India's largest neurological disease burdens, and unlike most conditions it is treated continuously, often for a decade or more, with no interruption tolerated — a missed refill can mean a seizure. That produces the most reliable repeat demand of any therapy class a distributor can carry. Valproic Acid's specific commercial strength is its breadth: because it covers generalised, focal, absence and myoclonic seizures, a neurologist can use it across a large share of their epilepsy book rather than reserving it for one seizure type, and the same molecule then extends into bipolar disorder and migraine prophylaxis. The prescriber base is small and concentrated — a district's neurologists and psychiatrists can be covered by a modest field effort — while the patient-level revenue runs for years. The molecule does, however, carry serious teratogenic and hepatic warnings, so it must be positioned as strictly specialist-led, prescription-only therapy.
Why Choose Cafoli Lifecare for Your Valproic Acid Franchise
- Monopoly rights — one partner per district, territory protected
- WHO-GMP certified manufacturing and DCGI-approved formulations
- Promotional inputs — visual aids, doctor literature, reminder gifts and MR bags
- 1000+ franchise partners across India
- On-time despatch, transparent net rates and dedicated order support
References
- PubChem — Valproic acid compound record, National Library of Medicine
- WHO Model List of Essential Medicines
- PubMed — clinical literature on valproate in epilepsy
Our formulations of Valproic Acid find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: